| | |
| Clinical data | |
|---|---|
| Other names | RU-27592; HR-592 |
| Drug class | Atypical antipsychotic; Major tranquilizer |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H19ClN2 |
| Molar mass | 274.79 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tepirindole (INN ; developmental code names RU-27592, HR-592) is a tryptamine-related atypical antipsychotic and major tranquilizer which was never marketed. [1] [2] [3] [4] [5] It is similar in structure to tryptamines but is not technically a tryptamine itself and is instead a dihydropyridinylindole. [1] [6] The drug is said to act on dopamine D2, serotonin 5-HT2, and α1-adrenergic receptors. [3] [4] It is a potent dopamine receptor antagonist but reportedly has little propensity to cause catalepsy and has been said to potentially be useful in treating the negative symptoms of schizophrenia. [4] [5] The drug may also act as a potent serotonin receptor agonist. [6] Tepirindole was first described in the literature by 1979. [1] [6]
Several potent blockers of DA receptors are also putative atypical antipsychotics. Tepirindole (HR-592, 25) has a high affinity for DA, 5-HT and NE receptors but has little propensity to cause catalepsy (78).